Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 154Breast Neoplasms 117Carcinoma, Non-Small-Cell Lung 66Triple Negative Breast Neoplasms 45Neoplasm Metastasis 45Neoplasms 44Lung Neoplasms 26Ovarian Neoplasms 25Squamous Cell Carcinoma of Head and Neck 24Stomach Neoplasms 23Melanoma 16Esophageal Neoplasms 16Adenocarcinoma 15Head and Neck Neoplasms 13Recurrence 12Esophageal Squamous Cell Carcinoma 12Cholangiocarcinoma 12Sarcoma 11Parkinson Disease 4, Autosomal Dominant Lewy Body 11Small Cell Lung Carcinoma 10Fallopian Tube Neoplasms 10Uterine Cervical Neoplasms 9Urinary Bladder Neoplasms 8Pancreatic Adenocarcinoma 8Colorectal Neoplasms 8Prostatic Neoplasms 7Inflammatory Breast Neoplasms 7Carcinoma, Pancreatic Ductal 7Breast Neoplasms, Male 7Biliary Tract Neoplasms 7

Interventions

durvalumab 1Gemcitabine 1Cisplatin 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Resectable Biliary Tract Cancer × Albumin-Bound Paclitaxel × Clear all
NCT05640791 2022-12-07

Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
40 enrolled
Gastrointestinal

Resectable Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡